|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction显示文摘 | Manal M. Hassan Ahmed Kaseb Carol J. Etzel Hashem El‐Serag Margaret R. Spitz Ping Chang Katherine S. Hale Mei Liu Asif Rashid Mohamed Shama James L. Abbruzzese Evelyne M. Loyer Harmeet Kaur Hesham M. Hassabo Jean‐Nicolas Vauthey Curtis J. Wray Basmah S. H | 2013 | Mol Carcinog2013，，1： | 2 |
| 2 | Powered Phlebectomy (TriVexTM) in Treatment of Varicose Veins显示文摘 | Nick Cheshire Steven M. Elias Blair Keagy R. Kolvenbach Austin L. Leahy W. Marston F. Pannier-Fischer Eberhard Rabe Gregory A. Spitz | 2002 | Annals of Vascular Surgery2002，，4： | 2 |
| 3 | Myeloperoxidase-Generated Oxidants Modulate Left Ventricular Remodeling but Not Infarct Size After Myocardial Infarction显示文摘 | Nikolay Vasilyev Timothy Williams Marie-Luise Brennan Samuel Unzek Xiaorong Zhou Jay W. Heinecke Douglas R. Spitz Eric J. Topol Stanley L. Hazen Marc S. Penn | 2005 | Circulation2005，，18： | 1 |
| 4 | New onset geriatric epilepsy: A randomized study of gabapentin, lamotrigine, and carbamazepine显示文摘 | A J. Rowan R E. Ramsay J F. Collins F Pryor K D. Boardman B M. Uthman M Spitz T Frederick A Towne G S. Carter W Marks J Felicetta M L. Tomyanovich | 2005 | Neurology2005，，11： | 1 |
| 5 | Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions显示文摘 | Isabelle Bedrosian MD James Schlencker MD Francis R. Spitz MD Susan G. Orel MD Douglas L. Fraker MD Linda S. Callans MD Mitchell Schnall MD PhD Carol Reynolds MD Brian J. Czerniecki MD PhD | 2002 | Annals of Surgical Oncology2002，，5： | 1 |
| 6 | O-055 Dietary phytoestrogens and lung cancer risk显示文摘 | M. Schabath L. Hernandez P. Pillow X. Wu M. Spitz | 2005 | Lung Cancer2005，，： | 1 |
| 7 | Overexpression of manganese or copper–zinc superoxide dismutase inhibits breast cancer growth显示文摘 | Christine J. Weydert Trent A. Waugh Justine M. Ritchie Kanchan S. Iyer Jenna L. Smith Ling Li Douglas R. Spitz Larry W. Oberley | 2006 | Free Radical Biology and Medicine2006，，2： | 1 |
| 8 | Abnormal enteric nerve morphology in atretic esophagus of fetal rats with adriamycin-induced esophageal atresia显示文摘 | W. Cheng A. E. Bishop L. Spitz J. M. Polak | 1999 | Pediatric Surgery International1999，，1： | 1 |
| 9 | Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer显示文摘 | Todd W. Bauer MD Francis R. Spitz MD Linda S. Callans MD Abass Alavi MD Rosemarie Mick MS Susan P. Weinstein MD Isabelle Bedrosian MD Douglas L. Fraker MD Thomas L. Bauer MD Brian J. Czerniecki MD PhD | 2002 | Annals of Surgical Oncology2002，，2： | 1 |
| 10 | 新生儿严重甲状旁腺功能亢进症:基因型/表现型间相关性和应用pamidronate作为抢救措施 | Waller S. Kurzawinski T. Spitz L. W.G.Van’t Hoff 高蕊 | 2005 | 世界核心医学期刊文摘(儿科学分册)2005，0，3： | 0 |
| 11 | 新生儿巨大脐突的分期修补 | Pacilli M. Spitz L. Kiely E.M. A. Pierro 杨周岐 | 2005 | 世界核心医学期刊文摘(儿科学分册)2005，0，11： | 0 |
| 12 | 阿列马嗪对Nissen胃底折叠术后干呕的控制效果显示文摘Background: Retching, an early component of the emetic reflex, is a common and distressing symptom in children after Nissen fundoplication. Alimemazine (trimeprazine, Vallergan; Castlemead, Herts, UK) is a phenothiazine derivative histamine1 antagonist, which anecdotally relieves the retching symptoms. Material and Methods: A prospective, double-blind, randomized, crossover, placebo-controlled study of 15 neurologically impaired children with retching after Nissen fundoplication over a period of 1 year (December 2002- December 2003). Patients were randomly allocated to receive 1 week each of alimemazine and placebo with crossover. A diary was maintained of retching episodes 1 week before, during, and 1 week after the trial. Dosage of alimemazine used was 0.25 mg/kg 3 times a day (maximum, 2.5 mg per dose). Statistical analysis was done using a paired Student’s t test, where P value of less than .05 was considered significant. Results are presented as mean ± SD. Results: Twelve parents completed the diaries (9 open, 3 laparoscopic Nissen fundoplication). Median age of the child was 36 months (8- 180 months), median duration of retching was 4.5 months (1- 52 months), and mean number of retching episodes per week was 60 ± 29.40. Mean number of retching episodes with alimemazine was 10.42 ± 9.48 vs 47.67 ± 27.79 with a placebo (P < .0001). No adverse effects were reported in those cases that completed the study. Conclusion: At low dose, alimemazine (Vallergan) is a safe and effective drug in the management of retching after Nissen fundoplication. | Antao B. Ooi K. Ade-Ajayi N. L. Spitz 刘凯 | 2006 | 世界核心医学期刊文摘(儿科学分册)2006，0，4： | 0 |
| 13 | 食管闭锁:高危组患儿的预后是否得到了改善显示文摘Purpose: The Spitz classification of oesophageal atresia (OA)-based on the birth weight and the presence of a major cardiac anomaly was proposed 1994. Advances in neonatal care have led us to question if these outcome figures are still valid. We tested the hypothesis that the outcome of neonates with OA has improved during the last decade. Methods: The records of all neonates (n = 188) born with OA and treated in a single institution between 1993 and 2004 were reviewed and compared with data from the original Spitz study. Data were obtained on the birth weight,presence of a major cardiac anomaly,and survival. Differences in survival were compared using the Yates-corrected χ 2 test. Results: In the early period,326 neonates survived (87.6% ) compared with 174 (91.5% ) in the most recent decade (P = 0.10). Based on Spitz classification,the outcome comparing both periods was the following: group I,97% (283/293) and 98.5% (130/132) (P = 0.44); group II,59% (41/70) and 82% (41/50) (P = 0.01); group III,22% (2/9) and 50% (3/6) (P = 0.57),respectively. Conclusions: The Spitz classification remains valid. It may be of use when counselling parents and in comparing outcome among centres. In our centre,the overall survival of neonates with OA has not significantly changed in the recent decade. The improvement in survival of neonates in group II,however,demonstrated the recent advances in neonatal。 | Lopez P.J. Keys C. Pierro A. L. Spitz 刘凯 | 2006 | 世界核心医学期刊文摘(儿科学分册)2006，0，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员